Skin sensitization evaluation is a mandatory biocompatibility endpoint for virtually all medical devices that contact patients, governed primarily by ISO 10993-10 and its Chinese harmonized counterpart GB/T 16886.10. This article provides a technical overview of the applicable standards framework, sample preparation and extraction requirements, in vivo and in vitro test methods, and the regulatory applications of sensitization testing for medical device manufacturers worldwide.
Technical Overview
Sensitization (delayed-type hypersensitivity, Type IV allergic reaction) testing evaluates the potential of chemical substances leaching from a medical device to induce an allergic immune response following repeated or prolonged patient contact. Small molecular leachables, such as residual monomers, accelerators, plasticizers, antioxidants, sterilant residues, and degradation products, can act as haptens that bind skin proteins and trigger T-cell-mediated sensitization. Because such reactions are persistent, unpredictable in severity, and cannot be reliably predicted from material composition alone, sensitization evaluation is treated as a fundamental endpoint in biological safety assessment.
The international framework for this evaluation is defined by the ISO 10993 series of standards. ISO 10993-1 establishes the risk-based, endpoint-driven evaluation strategy and the categorization of devices by nature of body contact (surface-contacting, external communicating, or implant) and contact duration (limited, prolonged, or permanent). ISO 10993-10 specifies the test methods for skin sensitization, while ISO 10993-12 governs sample preparation and reference materials. In China, the GB/T 16886 series adopts the ISO 10993 standards for national regulatory use. Key standards relevant to sensitization evaluation include:
- ISO 10993-1 — Biological evaluation of medical devices: evaluation and testing within a risk management process
- ISO 10993-10 — Tests for skin sensitization (current edition: ISO 10993-10:2021)
- ISO 10993-12 — Sample preparation and reference materials
- ISO 10993-17 and ISO 10993-18 — Toxicological risk assessment and chemical characterization of materials, which may support test waivers
- ISO 10993-2 — Animal welfare requirements applicable to in vivo studies
- GB/T 16886.10 — Chinese national standard harmonized with ISO 10993-10, referenced in NMPA submissions
- OECD Test Guidelines 406, 429, and the 442 series — reference methods for guinea pig assays, the local lymph node assay, and in chemico/in vitro alternatives
Under ISO 10993-1, sensitization testing is an expected endpoint for essentially all device categories involving direct or indirect patient contact, and any decision to exclude testing must be scientifically justified through a documented biological safety risk assessment aligned with ISO 14971.
Testing Samples
Surface-Contacting Devices
Devices contacting intact skin, mucosal membranes, or breached or compromised surfaces are evaluated for sensitization due to the direct exposure pathway of leachables to immune-competent tissue. Typical samples include adhesive patches, electrodes, wound dressings, compression bandages, surgical gowns and drapes, examination gloves, and contraceptive devices. For devices contacting breached or compromised surfaces, the sensitization requirement is applied with additional stringency because barrier function is diminished.
External Communicating Devices
Devices that communicate with the body indirectly through extracorporeal circulation or direct contact with tissue, bone, or blood are also within the scope of sensitization evaluation. Examples include intravenous infusion sets, catheters, cannulae, hemodialysis equipment, blood oxygenators, tubing sets, and endoscopes. Leachable chemicals from these devices may migrate into circulating fluids or tissues and induce systemic sensitization responses.
Implanted Devices
Long-term implants such as vascular stents, orthopedic implants, pacemaker leads, hernia meshes, and dental implants require sensitization assessment because leachables are released continuously at the implantation site over extended contact durations. For permanent-contact devices, evaluation must consider cumulative exposure to residual processing agents, sterilization by-products, and long-term degradation products.
Sample Preparation and Extraction
Sensitization testing is typically performed on device extracts prepared in accordance with ISO 10993-12. Extraction is designed to simulate worst-case clinical exposure by maximizing the release of leachable substances without degrading the material. Standard requirements include:
- Extraction ratios based on material form, for example 6 cm²/mL for materials thinner than 0.5 mm, 3 cm²/mL for materials of 0.5 mm to 1.0 mm thickness, and mass-based ratios of approximately 0.1 g/mL to 0.2 g/mL for irregular porous devices
- Simultaneous extraction in a polar solvent (physiological saline, water, or culture medium) and a non-polar solvent (vegetable oil such as cottonseed or sesame oil) to capture both hydrophilic and lipophilic leachables
- Standardized extraction conditions, typically 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, with the condition selected to be exaggerated but non-destructive relative to clinical use
- Testing of the final product in its sterilized, ready-to-use condition whenever feasible, using sterile technique for extracts intended for in vivo use
Testing Items
The core testing item is the assessment of delayed-type hypersensitivity potential, expressed as the capacity of device extracts or materials to induce skin sensitization in a validated model. The evaluation typically includes:
- Induction and challenge phases using polar and non-polar extracts at appropriate concentrations
- Grading of erythema and edema responses at specified observation time points (commonly 24 hours, 48 hours, and 72 hours after challenge) using the Magnusson and Kligman 0 to 3 grading scale for guinea pig methods
- Calculation of a Stimulation Index for local lymph node assay protocols
- Comparison of response incidence and intensity between test groups and negative and positive control groups, supported by statistical analysis
- Reporting of dose-response relationships and, where applicable, sensitization potency classification
A device extract is considered a sensitizer when the response in the treated group is statistically and biologically significantly greater than that of the concurrent control group under the conditions of the test.
Testing Methods
Guinea Pig Maximization Test (GPMT)
The Magnusson-Kligman guinea pig maximization test is an adjuvant-type assay and the most sensitive in vivo method specified in ISO 10993-10. Induction is performed by intradermal injection of the test extract together with Freund's complete adjuvant, followed by topical induction approximately one week later. After a rest period of about two weeks, a topical challenge is applied, and reactions are graded at 24 and 48 hours. Standard designs use 20 test animals with 10 controls, or a reduced design of 10 test animals with 5 controls. The GPMT is particularly suitable for device extracts in both polar and non-polar vehicles and can detect weak sensitizers.
Buehler Test
The Buehler test is a non-adjuvant, closed-patch topical method in which the test article is applied to the skin for 6-hour exposure periods, with induction repeated weekly over three weeks, followed by a rest interval and a challenge patch. Because exposure is entirely topical, the Buehler test is most appropriate for devices intended for intact skin contact. It is generally less sensitive than the GPMT but more closely mimics dermal exposure routes.
Local Lymph Node Assay (LLNA)
The local lymph node assay, conducted in accordance with OECD Test Guideline 429, is a refined and quantitative alternative to guinea pig methods. Test preparations are applied topically to the ears of mice on three consecutive days, and proliferation of lymphocytes in the draining auricular lymph nodes is measured on day six using radioisotope incorporation or a non-radioactive BrdU-ELISA variant. A Stimulation Index of 3 or greater indicates sensitization potential. The LLNA uses fewer animals, avoids adjuvant and challenge procedures, and is consistent with the 3Rs principles of animal welfare, though its applicability to dilute device extracts requires careful feasibility assessment regarding achievable test concentrations.
In Chemico and In Vitro Alternatives
New approach methodologies described in the OECD 442 series are increasingly used as part of a tiered, integrated strategy. These include the Direct Peptide Reactivity Assay (OECD TG 442C), which measures hapten reivity with cysteine and lysine peptides; KeratinoSens and LuSens assays (OECD TG 442D), which detect keratinocyte activation via the Nrf2 antioxidant response pathway; and h-CLAT and U-SENS assays (OECD TG 442E), which assess dendritic cell activation markers. Defined approaches combining two of three key events, as described in OECD TG 497, provide a predictive framework. However, because medical device extracts are complex mixtures that may cause cytotoxicity or solubility interference, regulatory acceptance of standalone in vitro sensitization assessment for devices is still evolving, and ISO 10993-10 positions such methods as complementary tools within a weight-of-evidence strategy.
Study Conduct and Quality Requirements
In vivo sensitization studies should be performed under the principles of Good Laboratory Practice with ethical review in accordance with ISO 10993-2. Manufacturers are advised to engage accredited third-party laboratories with validated protocols, documented positive control performance, and experience in extract-based testing to ensure that results are accepted by regulatory authorities across jurisdictions.
Applications
Sensitization evaluation results serve multiple purposes across the product lifecycle:
- Regulatory submissions, including U.S. FDA 510(k), De Novo, and PMA applications; technical documentation for CE marking under the EU MDR; NMPA device registration dossiers in China referencing GB/T 16886; and filings with other national authorities
- Biological safety evaluation files and biological evaluation plans and reports structured according to ISO 10993-1
- Design verification and material selection during research and development, enabling comparison of candidate polymers, elastomers, coatings, and adhesives
- Change control, where modifications to materials, suppliers, manufacturing processes, molding parameters, or sterilization methods trigger re-evaluation of sensitization risk
- Support for sterilization validation, including assessment of ethylene oxide residues and radiation-induced degradation products
- Chemical characterization and toxicological risk assessment programs under ISO 10993-18 and ISO 10993-17, where sensitization data complement extractables and leachables profiles
- Due diligence for combination products, reprocessed reusable devices, and additive-manufactured components with novel surface characteristics
FAQ
When is sensitization testing required for a medical device?
ISO 10993-1 identifies sensitization as an expected endpoint for all devices with patient contact, regardless of contact category or duration. Testing may be omitted only when a documented risk assessment based on material data, chemical characterization, and clinical literature provides a robust scientific justification.
Which sensitization test method should be selected?
The GPMT is preferred for maximal sensitivity with device extracts, particularly for mucosal, blood-contacting, and implanted devices. The Buehler test suits intact-skin-contacting products, while the LLNA offers a refined, quantitative alternative where extract concentrations can be achieved. Method selection should consider the route of clinical exposure, extract solvent, and regulatory expectations in the target market.
Why are both polar and non-polar extraction solvents used?
Leachable substances vary widely in polarity, and a single solvent cannot exhaustively extract both hydrophilic and lipophilic chemicals. Dual extraction in saline or culture medium and vegetable oil ensures that the test system evaluates the broadest realistic profile of releasable sensitizing agents.
Can in vitro methods fully replace animal sensitization tests?
Not yet for most devices. In chemico and in vitro assays defined in the OECD 442 series are valuable screening and weight-of-evidence tools, but the complex, dilute, and cytotoxic nature of many device extracts currently limits their standalone regulatory acceptance for medical device biocompatibility.
Can sensitization testing be waived through chemical characterization?
Yes, in defined circumstances. Where ISO 10993-18 chemical characterization identifies all extractable substances and a ISO 10993-17 toxicological risk assessment demonstrates that sensitization thresholds are not exceeded, regulators may accept a justification for waiving animal testing, provided the data package is complete and defensible.
How often must sensitization evaluation be repeated?
A valid sensitization study remains applicable as long as the device design, materials, manufacturing process, and sterilization method are unchanged. Any significant change, including supplier substitution or process requalification, requires reassessment of biological safety, which may or may not necessitate new testing.